ZappRx Inc., a healthcare tech company headquartered in Boston, and Teva Respiratory LLC, a US-based pharmaceutical company, have reportedly signed a collaboration deal to improve the delivery of specialty respiratory medication.
Reportedly, the joint project is likely to render an efficient approach towards prescribing and administering therapies vital for patients and to manage their diseases as well as symptoms in a better way.
ZappRx stated that its cloud-based platform streamlines a multi-step, manual process of prescribing, sometimes having many other platforms involved for various treatments, into a digitally-enabled format. This potentially helps asthma treatment providers to lay greater focus on patient care.
As per authentic sources, Teva Respiratory, based in Pennsylvania (USA), specializes in developing pharmaceutical products that aid in the treatment of asthma, exercise-induced bronchospasm and prolonged obstructive pulmonary diseases. Teva Respiratory, for the record, operates as one of the subsidiaries of Teva Pharmaceutical Industries Ltd.
Zoë Barry, the Chief Executive Officer & Founder of ZappRx, was reportedly quoted saying that the company’s partnership with an industry leader like Teva Respiratory enables it to make life-altering specialty medications more widely accessible to an underserved population of patients. The latest move is first and foremost dedicated towards helping patients and the company believes in the support it would be receiving from Teva Respiratory, Barry further commented.
For the uninitiated, ZappRx is highly involved in enhancing efficiencies in the collection and maintenance of a multitude of requisite information such as prior/payer authorization requirements, pharmacy information and relevant medical history for the ordering of specialty drugs.
Currently, the ZappRx platform is actively involved in PAH (Pulmonary Arterial Hypertension), Pulmonary Cystic Fibrosis (CF), Cardiology including Congestive Heart Failure and Hyperlipidemia, and Gastroenterology including Ulcerative Colitis and Crohn’s Disease. Apparently, ZappRx is further planning to extend into other areas such as Neurology, Oncology and Rheumatology.